I am a board-certified psychiatrist and volunteer Assistant Professor at The Johns Hopkins University School of Medicine. I have advanced training as a behavioral pharmacologist and postdoctoral research fellow with the Johns Hopkins Center for Psychedelics and Consciousness Research. I completed medical school and residency training with Baylor College of Medicine and the Menninger Department of Psychiatry and Behavioral Sciences, receiving awards for excellence in psychotherapy and research. I am also a graduate of Texas A&M University, where I studied Biochemistry, Genetics, and English, and graduated with University Honors and Honors Fellows Distinctions.

As a clinician, I treat individuals struggling with a variety of conditions, including depression, anxiety, and trauma. My approach to psychotherapy is broadly informed and focused most on helping people cultivate deeper relationships with themselves and others, so they can live in ways that feel resilient, vibrant, and true. I acknowledge the harm that has come from the over-medicalization of suffering and believe in only the judicious use of psychiatric medications. Decisions around prescribing or de-prescribing are made collaboratively with patients and include careful exploration of the reasons for medication change, the best available evidence, and risk-benefit analysis.

As a researcher, I have investigated and produced numerous scientific publications on topics such as behavioral models of addiction and cognitive impairment, the neuropsychiatric effects of cannabis, and the complex properties of psychedelic-type therapies like ketamine, MDMA, and psilocybin. I have worked as a scientific collaborator, study physician, and session therapist for multiple clinical trials of psilocybin-assisted interventions. I have also worked as a physician-investigator for Phase 1 – 3 schizophrenia and depression drug development studies. These opportunities have for me highlighted the unique potential for psychedelics to facilitate healing and enhance wellbeing when used under appropriate conditions that consider drug risk and benefit. I am committed to the eventual development of these tools within healthcare infrastructures that are safe, sustainable, and put people first.

See curriculum vitae.